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Abstract
Background: Discoidin domain receptors 1 (DDR1), a subtype of DDRs, has been reported as a critical modulator of
cellular morphogenesis, differentiation, migration and invasion.
Methods and results: In this study, we investigated the expression of DDR1 and its clinical association in Chinese
patients with pancreatic ductal adenocarcinoma (PDAC). Across a cohort of 30 patients, we examined DDR1
expression in paired PDAC and corresponding adjacent non-tumor tissues by real-time quantitative PCR (RT-qPCR),
or western blotting. DDR1 expression is significantly higher in PDAC, as compared to normal adjacent tissue,
confirming results from the Oncomine databases. We validated DDR1 expression by immunohistochemistry across a
non-overlapping cohort of 205 PDAC specimens. Kaplan-Meier survival curves indicate that increased expression of
DDR1 is associated with a poor prognosis in PDAC patients (P = 0.013). Multivariate Cox regression analysis
identified DDR1 expression, age, N classification and liver metastasis as independent prognostic factors in PDAC.
Conclusions: This study demonstrated that DDR1 can well serve as a novel prognostic biomarker in PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a devastat-
ing disease and the fourth most common disease-related
mortality worldwide [1, 2]. The 5-year survival is approxi-
mately 6 %, and only 20 % of patients present with resect-
able disease [3, 4]. Few PDAC cases (less than 10 %) are
diagnosed at early stages [5], largely due to the absence of
specific symptoms, and as such patients often present with
advanced stage disease. Hence, the identification of novel
prognostic indicators has become a major topic of interest
to the PDAC research community at large.
The discoidin domain receptor 1 (DDR1) belongs to a
subfamily of Receptor tyrosine kinases (RTKs) character-
ized by the presence of an extracellular discoidin homology
domain that function to modulates cell proliferation and
differentiation. DDRs are non-integrin collagen receptors
composed of two types, DDR1 and DDR2, independently
activated by receptor-specific collagens binding at the dis-
coidin domain [6]. DDR1 can be alternatively spliced into
five isoforms (DDR1a-e). Recently, studies have suggested
DDR1 participates in several critical cell processes includ-
ing: adhesion, migration, proliferation, and invasion [7–9].
Moreover, expression of DDR1 is known to be dysregulated
in multiple human cancers such as lung, breast, hepatic,
and ovary cancers, suggesting a previously unappreciated
role of DDR1 in tumor formation and progression [10–13].
In PDACs, however, the role of DDR1 remains to be
uncharacterized.
In this retrospective study, we examined the expres-
sion pattern of DDR1 at the mRNA and protein level
and explored the relationship of DDR1 expression with
clinicopathologic parameters, including overall survival.
We found that the expression of DDR1 was associated
with poor prognosis of Chinese PDAC patients.* Correspondence: lordhuarong@sohu.com; syw0616@126.com
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This research was approved by the Ethics Committee of
Ren Ji hospital, School of Medicine, Shanghai Jiao Tong
University, and written informed consent was obtained
from each patient involved in this study.
Patients and tissue specimens
We retrospectively analyzed clinical and pathological
characteristics of 205 patients who had resectable infil-
trating PDAC and underwent surgical resection at the
Biliary-Pancreatic Department of Ren Ji Hospital,
School of Medicine, Shanghai Jiao Tong University,
China, from January 2002 to June 2014 (see Table 1).
Patients who had history of other solid tumors, received
preoperative chemotherapy, radiotherapy or other anti-
cancer therapies were excluded from this study. Stand-
ard pancreatectomy was undergone with lymph node
dissection in patients who had no evidence of distant
organ metastasis. Routine chemotherapy with gemcitabine
had been given to all patients after operation, but no
radiation treatment was done in any of the patients in-
cluded in our study [14]. An additional 30 fresh frozen tis-
sues of PDAC and corresponding adjacent non-tumor
tissues (located more than 2 cm apart from the tumor tis-
sue in each case) were also obtained from the same de-
partment [15]. The diagnosis was confirmed by two
clinical pathologists.
RNA extraction and real-time quantitative PCR (RT-qPCR)
Total RNA from primary tumor and adjacent non-tumor
tissue samples was isolated with Trizol reagent (Takara,
Japan), and reversely transcribed through PrimeScript RT-
qPCR kit (Takara, Japan) according to the manufacturer’s
instructions [16]. RT-qPCR was performed using a 7500
RT-qPCR system (Applied Biosystems, Inc. USA) with a
15-μl PCR mix containing 0.5 μl of cDNA, 7.5 μl of 2*SYBR
Green master mix (Invitrogen, Carlsbad, California, USA),
and 200 nM of the appropriate primers (Invitrogen,
Carlsbad, California, USA). Primer sequences set for
DDR1 detection were as follows: forward primer: 5’-
GCGTCTGTCTGCGGGTAGAG-3’, reverse primer: 5’-
ACGGCCTCAGATAAATACATTGTCT-3’. The relative
levels of mRNA expression were calculated based on the
difference between amplification of DDR1 and β-actin
RNA (forward: 5’-ACTCGTCATACTCCTGCT-3’, reverse:
5’- GAAACTACCTTCAACTCC-3’) using the 2-ΔΔct
method [17]. To minimize technical (run-to-run) variation
between the samples, all samples were analyze d in the
same run for both target genes and reference genes. All ex-
periments were performed three times with three technical
replicates.
Table 1 Association between DDR1 expression and
clinicopathologic features in patients with PDAC
DDR1 Expression
Characteristics High Low P value
Total (n = 126) (n = 79) (χ2 test)
Age (years)
Mean (years) 65.19 66.82 62.69 0.374
< 65 107 65 42 0.826
≥ 65 98 61 37
Gender 0.891
Male 117 74 43
Female 88 52 36
Tumor location 0.273
Head 139 89 50
Body/tail 66 37 29
Size 0.551
≤ 2 cm 27 18 9
> 2 cm 178 108 70
Tumor differentiation 0.054
Well 11 10 1
Moderate/poor 194 116 78
T classification 0.697
T1 11 8 3
T2 31 18 13
T3 125 73 52
T4 38 20 18
N classification 0.858
Absent 136 83 53
Present 69 43 26
AJCC stage 0.949
Stage I 38 20 18
Stage II 135 73 62
Stage III 21 10 11
Stage IV 14 7 7
Liver metastasis 0.560
Absent 191 118 73
Present 14 8 6
Vascular invasion 0.801
Absent 177 109 68
Present 28 17 11
Vital status 0.912
Dead 172 106 66
Alive 33 20 13
AJCC staging is according to the 7th edition of the American Joint Committee
on Cancer (AJCC) staging system [29]
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Western blotting analysis
Western blotting was performed as previously described
[18]. The DDR1 antibody was purchased from Proteintech
Inc. and species-specific secondary antibody was pur-
chased from Cell Signaling, Beverly, MA. Bound second-
ary antibodies were detected by Odyssey imaging system
(LI-COR Biosciences, Lincoln, NE).
Tissue microarray (TMA) construction
Tissue microarrays (TMA) were constructed using
diameter of 1.5-mm cores including 205 cases of
matched tumor and non-tumor tissues specimens. After
screening and marking representative spots of tissues,
the tissues were punched out and squeezed into the
paraffin array blocks.
Immunohistochemical (IHC) staining and scoring
Immunohistochemical staining was performed on a tissue
microarray (TMA) containing 205 paired PDAC samples as
previous described [3]. Scoring was calculated according to
the sum of the percentage of positively stained tumor cells:
0–5 % scored 0; 6 %–35 % scored 1; 36 %–70 % scored 2;
more than 70 % scored 3 and the staining intensity: no
staining scored 0, weakly staining scored 1, moderately
staining scored 2 and strongly staining scored 3, respect-
ively. The final score was designated as low or high expres-
sion group using the percentage of cells staining positive
multiplied by the staining intensity as follows: “-” for a score
of 0–1, “+” for a score of 2–3, “++” for a score of 4–6 and
“+++” for a score of > 6; low expression was defined as a
total score < 4 and high expression with a total score ≥ 4.
Fig. 1 DDR1 expression is increased in PDAC at mRNA level. a increased DDR1 mRNA expression in 30 matched tumor (T) and non-tumor tissue
(N) was detected by real-time quantitative PCR. b DDR1 expression in Buchholz pancreas grouped by normal pancreatic duct (1) and PDAC (2)
Fig. 2 DDR1 protein expression in PDAC tissue samples. a-e Immunohistochemical representative images of DDR1 expression in PDAC compared
with surrounding noncancerous pancreas (SNP) analyzed by immunohistochemisty; a PDAC, scored as (+++); b PDAC, scored as (++); c PDAC,
scored as (+); d PDAC, scored as (-); e Normal pancreas, scored as (-). f Western blots of DDR1 expression in four pairs of PDAC patients
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These scores were determined independently by two senior
pathologists. The scoring by the pathologists was done in a
blinded manner.
Follow-up
The postoperative follow-up included clinical and labora-
tory examinations. OS, a measure of prognosis, was defined
as the time from the date of surgery to the date of death or
the last follow-up examination.
Statistical analysis
All statistical analyses were performed using SPSS 19.0
(SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5
(San Diego, CA) software. DDR1 mRNA in the tumor
and adjacent non-tumor tissue samples were compared
using a paired-samples t test. The Chi-square test and
Fisher’s exact probability method was used to analyze the
relationship between DDR1 expression and clinicopatho-
logical characteristics. Survival curves were evaluated
using the Kaplan-Meier method, and differences between
survival curves were tested by the log-rank test. Cox pro-
portional hazards regression model was used to examine
univariate and multivariate hazard ratios for the study var-
iables. Only significantly different variables in univariate
analysis including DDR1 expression level, Age, N classifi-
cation, Liver metastasis were entered into the next multi-
variate analysis [19]. A two-sided P-value < 0.05 was
considered statistically significant.
Results
DDR1 is transcriptionally upregulated in PDAC
We evaluated the transcript levels of DDR1, by RT-
qPCR, using 30 pairs of specimens from PDAC patients.
The DDR1 mRNA levels were significantly increased in
19/30 PDAC tissue samples compared with the matched
adjacent non-tumor tissue samples (P = 0.002, Fig. 1a).
Additionally, we analyzed a microarray datasets from
Oncomine databases showed in Fig. 1b [20] and found
mRNA expression levels of DDR1 was consistent with
our data.
DDR1 expression at protein level in PDAC
Based on the IHC scoring criterions established (see
methods), 126 of 205 (61.5 %) PDACs specimens showed
high DDR1 expression (DDR1 ++ or DDR1 +++), whereas
Fig. 3 DDR1 expression is correlated with overall survival rate in
PDAC patients. Kaplan-Meier survival curves show high expression
level of DDR1 was significantly correlated with poor survival of PDAC
(log-rank test: P = 0.009)
Fig. 4 Comparisons of overall survival between DDR1 high expression and DDR1 low expression in early clinical stage (I-II) cohort and in
advanced clinical stage (III-IV) cohort. P-values were calculated by log-rank test
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the remaining 79 cases (38.5 %) displayed low DDR1 ex-
pression (DDR1- or DDR1 +) (Fig. 2 a-e). We valdated the
protein overexpression across 4 pairs of resected represen-
tative specimens (tumor tissues and matched adjacent non-
tumor tissues) from PDAC patients using Western blotting
analysis. Consistent with the RT-qPCR results, an in-
crease in DDR1 expression was observed in all of the 4
PDAC tissues compared with the matched adjacent
non-tumor tissues (Fig. 2f ).
Correlation of DDR1 expression with clinicopathological
features of PDAC
To determine the relationship between DDR1 expres-
sions with the clinicopathological features of PDAC, the
IHC staining of DDR1 levels were statistically evaluated
by the Chi-square tests. The clinicopathologic parame-
ters in PDAC included: age, gender, clinical stage, liver
metastasis, vascular invasion and differentiation status.
As shown in Table 1, no significant differences were found
between DDR1 expression and any other parameters.
Correlation of DDR1 expression and prognosis in PDAC
patients
The patients’ survival analysis was evaluated by
Kaplan-Meier analysis and log-rank test. As shown in
Fig. 3, there exists a negative correlation between
DDR1 expression and overall survival (P =0.013). The
association between DDR1 expression and overall sur-
vival in PDAC patients was also evaluated with regards
to clinical stages, status of lymphatic metastasis and
vascular invasion (Fig. 4, 5 and 6). The overall survival
time was significantly different between patients with
low and high DDR1 expression (P < 0.05), with the low
DDR1 group having a longer overall survival independ-
ent of the clinical stage, status of lymphatic metastasis
and vascular invasion.
Fig. 5 Comparisons of overall survival between DDR1 high expression and DDR1 low expression in patients with or without lymph node
metastasis. P-values were calculated by log-rank test
Fig. 6 Comparisons of overall survival between DDR1 high expression and DDR1 low expression in patients with or without vascular invasion.
P-values were calculated by log-rank test
Huo et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:88 Page 5 of 7
Univariate and multivariate analyses
Univariate and multivariate analyses were performed
to compare the impact of DDR1 expression and other
clinical and pathological parameters across our cohort
(Table 2). Based on results of the univariate analyses,
the age, DDR1 expression, N classification and Liver
metastasis were significantly associated with overall
survival. Furthermore, all these 4 factors were included
in a multivariate Cox regression analysis to adjust for
the effects of the covariates and were confirmed as in-
dependent prognostic factors.
Discussion
Previously studies have identified DDR1 is overexpressed
in various human invasive tumors including lung, breast,
hepatic, and ovary cancers, highlighting its possible role in
tumor initiation, maintenance or progression [10–13]. In
the present study, DDR1 expression and its association
with clinicopathological features including prognosis were
investigated across a cohort of Chinese PDAC patients.
We determined that DDR1 expression was increased in
Chinese PDAC patients at both the mRNA and protein
level. These findings are supported by non-overlapping data
from an Oncomine database, which highlights the same
trends in PDAC. We expanded our analysis to a non-
overlapping cohort of 205 patients and determined that
DDR1 expression was upregulated in 126/205 PDAC speci-
mens. Elevated DDR1 expression has also been reported in:
(i) 52.2 % of hepatocellular carcinoma samples [11]; (ii)
61.0 % of non-small cell lung cancer [21]; and (iii) 63 % of
serous ovarian cancer tissues [13]. The overexpression of
DDR1 in these different human cancers support the
hypothesis that DDR1 may impact tumorigenesis and/or
tumor progression.
Previous studies indicated that DDR1 could promote
tumor progression by inducing cell adhesion and differenti-
ation, which might be due to: (i) coexpressing with adhe-
sion molecules [22]; (ii) promoting epithelial-mesenchymal
transition (EMT) [21, 23]; (iii) participating in functional
interaction of Notch1 and NF-κB pathway [24, 25]. Further-
more, survival analysis in our study revealed that PDAC
patients with high DDR1 expression levels had significantly
shorter survival times than those with low expression levels.
Univariate analyses showed that increased DDR1 ex-
pression was significantly associated with the overall
survival rate in PDAC patients. Multivariate analysis
demonstrated that DDR1 expression, together with
some traditional prognostic factors, such as age, N stage
and liver metastasis, were independent risk factors in
the prognosis of PDAC patients. These results suggested
that DDR1 may represent a novel prognostic marker for
PDAC patients.
The precise molecular mechanisms through which
DDR1’s impacts on tumor development and differenti-
ation have yet to be elucidated. DDR1 presents 15
tyrosine residues in cell’s cytoplasmic regions, which
are potential sites for phosphorylation and receptor ac-
tivation by different types of collagens [6, 12, 26]. It
has been shown that over-expression of DDR1 in-
creased the migration and invasion of hepatoma cells
in vitro, which implicated a role of DDR1 in tumor
progression and metastatic dissemination [27]. Re-
duced or absent DDR1 expression in vivo leads to de-
fects in placental implantation and development of
mammary gland [28], while Miao et al.[21] demon-
strated that DDR1 expression promoted epithelial-to-
mesenchymal transition and contributed to non-small-
cell lung cancer cells migration and invasion. The signaling
Table 2 Univariate and multivariate analyses of prognostic parameters for survival in patients with pancreatic ductal
adenocarcinoma (PDAC)
Univariate analysis Multivariate analysis
Prognostic parameter RR 95 % CI P value RR 95 % CI P value
DDR1 (low vs.high) 0.613 0.439–0.857 0.004a 0.643 0.457–0.904 0.011a
Age (<65 vs. ≥65) 1.460 1.066–2.000 0.019a 1.533 1.107–2.122 0.010a
Gender (male vs. female) 0.765 0.552–1.058 0.105
Tumor location (head vs. body/tail) 0.999 0.713–1.399 0.996
Size (≤2 cm vs. >2 cm) 1.641 0.978–2.754 0.061
Tumor differentiation (well vs. moderate/poor) 2.125 0.938–4.813 0.071
T classification (T1 vs. T2 vs. T3 vs. T4) 1.104 0.871–1.400 0.412
AJCC stage (I vs. II vs. III vs. IV) 1.260 0.992–1.600 0.059
N classification (absent vs. present) 1.811 1.290–2.541 0.001a 1.769 1.242–2.519 0.002a
Liver metastasis (absent vs. present) 3.299 1.746–6.235 0.000a 2.748 1.419–5.320 0.003a
Vascular invasion (absent vs. present) 1.492 0.955–2.334 0.079
HR hazard ratio, CI confidence interval
AJCC staging is according to the 7th edition of the American Joint Committee on Cancer (AJCC) staging system [29]
aStatistical significant (P < 0.05)
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pathways contributed by DDR1 upon cell-matrix inter-
action remain elusive and need further investigation.
In conclusion, this study demonstrated that DDR1 might
serve as a novel prognostic biomarker in PDAC. Import-
antly, the molecular mechanisms underlying the relation-
ship described above require clarification. Further studies
are needed to investigate the molecular pathways involved
in the regulation of DDR1, to improve our understanding
and explore the possible therapies.
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